Novel gyrA point mutation in a strain of Escherichia coli resistant to fluoroquinolones but not to nalidixic acid.
We have previously described a clinical isolate of Escherichia coli (Q2) that is highly resistant to fluoroquinolones (MIC of ciprofloxacin, 16 micrograms/ml) but susceptible to nalidixic acid (MIC of nalidixic acid, 4 micrograms/ml) (N. Moniot-Ville, J. Guibert, N. Moreau, J.F. Acar, E. Collatz, an...
Zapisane w:
| Wydane w: | Antimicrob Agents Chemother |
|---|---|
| Główni autorzy: | , , , |
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
American Society for Microbiology (ASM)
1993
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC187948/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/8392306/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.37.6.1247 |
| Etykiety: |
Nie ma etykietki, Dołącz pierwszą etykiete!
|